Introduction: Results obtained from PRIMAVERA study have demonstrated that 7.5% of obese individuals does not respond to sibutramine therapy. The aim of the study was to evaluate if GNB3, SERT, NET, TPH2 genes polymorphisms are associated with the results of obesity treatment with sibutramine.
Methods: 69810 obese patients took sibutramine for at least 3 months. According to the results of 3 months therapy, we formed two groups of patients: 1) < 5% of body weight reduction non-responders (n=52, mean age 43.6 years) 2) clinically significant weight loss ≥ 5% -responders (n=66, mean age 43.7 years). The second group was elected by paired comparison method from PRIMAVERA database. Also GNB3, SERT, NET, TPH2 genes polymorphisms were assessed.
Results: We did not find significant correlations between SERT, NET and TPH2 genes polymorphism and body weight loss. GNB3 TT genotype was more frequent in significant weight loss group (responders) (P=0.022). We evaluated body weight loss and BMI change in patients with different genotypes of GNB3 C825T polymorphism in the whole group (n=118). Sibutramine treatment resulted in significantly greater weight loss in patients with TT genotype than in CC/CT genotype carriers (−9.35% vs −6.45%, P=0.03).
|Body weight loss|
|CC and CT genotypes (n=93)||−5.1 (−8.75; −2.91)||0.034*||−5 (−8; −3)||0.018*|
|TT genotype (n=25)||−8.24 (−10.34; −6.12)||−8 (−12; −5)|
Conclusions: 1. GBN3 gene TT genotype was associated with more effective weight loss during sibutramine treatment; 2. Treatment results were not effected by SERT, NET and TPH2 genes polymorphisms.
18 - 21 May 2019
European Society of Endocrinology